alexa Tiny Droplets To Detect Cancer Biomarkers

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th International Conference on Biomarkers & Clinical Research
April 15-17, 2014 St. Hilda’s College - University of Oxford, UK

Taly Valerie
ScientificTracks Abstracts: J Mol Biomark Diagn
DOI: 10.4172/2155-9929.S1.021
D roplet-based microfluidic has led to the development of highly powerful systems that represent a new paradigm in High- Throughput Screening where individual assays are compartmentalized within microdroplet microreactors. By combining a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. Droplets (in the pL to nL range) are produced as independent microreactors that can be further actuated and analyzed at rates of the order of 1000 droplets per seconds. Added to the flexibility and versatibility of platform designs, such progress in sub-nano liter droplet manipulation allows for a level of control that was hitherto impossible. We will show how by combining microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of mutant sequences within a high quantity of non-mutated sequences in complex mixture of DNA with sensitivity unreachable by conventional procedures. Finally, to demonstrate the pertinence of our procedures to overcome the clinical oncology challenges, the results of 2 studies will be presented. When the first one addresses our ability to detect minoritary subclones in colorectal tumors and to understand the impact of these subclones on responses and survival of the patients treated by anti-EGFR therapies, the second one aims at demonstrated the possibility to circulating tumor DNA in plasma of patients with advanced colorectal cancers.
Taly Valerie conducts her research at the interface between chemistry, physics and biology. Since 2003, she has been working with Prof. Andrew Griffiths, first in the Medical Research Council in Cambridge (UK) and then in the ISIS (Strasbourg). She focuses her research on in vitro compartmentalization of biological and chemical reactions in emulsion droplets of few picoliters. She recently started the Translational Research and Microfluidics Group within the clinical oncology research unit headed by Prof. P. Laurent-Puig. Her research is dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version